Korean J Ophthalmol.  2016 Aug;30(4):295-301. 10.3341/kjo.2016.30.4.295.

The Application of a New Maximum Color Contrast Sensitivity Test to the Early Prediction of Chiasma Damage in Cases of Pituitary Adenoma: The Pilot Study

• Slatkeviciene G
• Liutkeviciene R
• Glebauskiene B
• Zaliuniene D
• Kriauciuniene L
• Bernotas G
• Tamasauskas A

• KMID: 2373990
• DOI: http://doi.org/10.3341/kjo.2016.30.4.295

Abstract

PURPOSE
Our objective was to estimate the maximum color contrast sensitivity (MCCS) thresholds in individuals with chiasma opticum damage.
METHODS
The pilot study tested 41 people with pituitary adenoma (PA) and 100 age- and gender-matched controls. Patients were divided into two groups according to PA size, PA ≤1 cm or PA >1 cm. A new MCCS test program was used for color discrimination.
RESULTS
The mean total error score (TES) of MCCS was 1.8 in the PA ≤1 cm group (standard deviation [SD], 0.38), 3.5 in the PA >1 cm group (SD, 0.96), and 1.4 in the control group (SD, 0.31; p < 0.001). There was a positive correlation between tumor size and MCCS result (r = 0.648, p < 0.01). In the group that had PA-producing hormones, the TES was 2.5 (SD, 1.09), compared to 4.2 value in the non-functioning PA group of patients that did not have clinically significant hormone excess (SD, 3.16; p < 0.01). In patients with normal visual acuity (VA) or visual field MCCS, the TES was 3.3 (SD, 1.8), while that in patients with VA <0.00 was 4.6 (SD, 2.9).
CONCLUSIONS
Results of the MCCS test TES were 1.9 times better in patients with PA ≤1 cm compared to patients with PA >1 cm (p < 0.01). In PA patients with normal VA, the TES was 2.35 times worse than that of healthy persons (p < 0.01).

Keyword

Macroadenoma; Maximum color contrast sensitivity; Micoradenoma; Pituitary; Visual function impairment

MeSH Terms

Adenoma/*complications/diagnosis
Adolescent
Adult
Aged
Color Perception/physiology
Color Perception Tests/*methods
Contrast Sensitivity/*physiology
*Early Diagnosis
Female
Humans
Male
Middle Aged
*Optic Chiasm
Pilot Projects
Pituitary Neoplasms/*complications/diagnosis
Time Factors
Vision Disorders/*diagnosis/etiology/physiopathology
Visual Fields
Young Adult

Reference

1. Page RB. Sellar and parasellar tumors. In : Wilkins RH, Rengachary SS, editors. Neurosurgery. 2nd ed. New York: McGraw-Hill;1996. p. 791–804.

2. Nistor R, editor. Pituitary tumours. New York: NeuroReview;1996. p. 264–272.

3. Schoemaker MJ, Swerdlow AJ. Risk factors for pituitary tumors: a case-control study. Cancer Epidemiol Biomarkers Prev. 2009; 18:1492–1500.

4. Schoemaker MJ, Swerdlow AJ. Risk of pituitary tumors in cellular phone users: a case-control study. Epidemiology. 2009; 20:348–354.

5. Oruckaptan HH, Senmevsim O, Ozcan OE, Ozgen T. Pituitary adenomas: results of 684 surgically treated patients and review of the literature. Surg Neurol. 2000; 53:211–219.

6. Henkind P, Gold D. Systemic ophthalmology. In : Tasman W, editor. Duane's clinical ophthalmology. Philadelphia: Lippincott-Raven Publishers;1996. p. 8–12.

7. Kanski JJ. Neuro-ophthalmology. In : Kanski JJ, editor. Clinical ophthalmology: a systemic approach. Oxford: Butterworth-Heinemann;1994. p. 480–483.

8. Poon A, McNeill P, Harper A, O'Day J. Patterns of visual loss associated with pituitary macroadenomas. Aust N Z J Ophthalmol. 1995; 23:107–115.

9. Ginsburg AP. Contrast sensitivity and functional vision. Int Ophthalmol Clin. 2003; 43:5–15.

10. Liutkeviciene R, Zaliuniene D, Stanislovaitiene D, Jasinskas V. Associations between color perception and optic nerve disk drusen. Medicina (Kaunas). 2010; 46:821–826.

11. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer. 2002; 2:836–849.

12. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96:273–288.

13. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004; 101:613–619.

14. Asa SL. Tumors of the pituitary gland. In : Rosai J, editor. Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology;1998. p. 1–214.

15. Cooper O, Melmed S. Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab. 2012; 26:447–460.

16. Sinkunas K. Factors influencing an effect on the results of surgery for pituitary adenomas [dissertation]. Kaunas: Kaunas University of Medicine;2008.

17. Birch J, editor. Diagnosis of defective colour vision. Oxford: Boston Butterworth-Heinemann;2001. p. 149–156.

18. Elgamal EA, Osman EA, El-Watidy SM, et al. Pituitary adenomas: patterns of visual presentation and outcome after transsphenoidal surgery. An institutional experience. Internet J Ophthalmol Vis Sci. 2007; 4:http://faculty.ksu.edu.sa/68905/Lectures/mhtml%20file%20F%20Pituitary%20Adenomas.pdf.

19. Dhar MY, Pehere NK. Unusual visual manifestations of pituitary tumours. Kerala J Ophthalmol. 2007; 19:147–155.

20. Hollenhorst RW, Young BR. Ocular manifestations produced by tumours of pituitary gland: analysis of 1000 cases. In : Kohler PO, Ross GT, editors. Diagnosis and treatment of pituitary tumours. Amsterdam: Excerpta Medica;1973. p. 53–68.

21. Anderson D, Faber P, Marcovitz S, et al. Pituitary tumors and the ophthalmologist. Ophthalmology. 1983; 90:1265–1270.

22. Jayaraman M, Ambika S, Gandhi RA, et al. Multifocal visual evoked potential recordings in compressive optic neuropathy secondary to pituitary adenoma. Doc Ophthalmol. 2010; 121:197–204.

23. Dhasmana R, Nagpal RC, Sharma R, et al. Visual Fields at Presentation and after Trans-sphenoidal Resection of Pituitary Adenomas. J Ophthalmic Vis Res. 2011; 6:187–191.

24. Mejico LJ, Miller NR, Dong LM. Clinical features associated with lesions other than pituitary adenoma in patients with an optic chiasmal syndrome. Am J Ophthalmol. 2004; 137:908–913.

25. Grochowicki M, Vighetto A, Berquet S, Sassolas G. Contrast sensitivity function and pituitary adenoma: a study of 40 cases. Br J Ophthalmol. 1990; 74:358.

26. Kasputyte R, Slatkeviciene G, Liutkeviciene R, et al. Changes of visual functions in patients with pituitary adenoma. Medicina (Kaunas). 2013; 49:132–137.

27. Gupta A, Khandalavala B, Bansal RK, et al. Atrophy of myelinated nerve fibers in pituitary adenoma. J Clin Neuroophthalmol. 1990; 10:100–102.